RANKL inhibition: A novel strategy to decrease femoral head deformity after ischemic osteonecrosis

Journal of Bone and Mineral Research

Volumn 21, Issue 12, 2006, Pages 1946-1954

  Kim, Harry K W ^a   Morgan Bagley, Stephanie ^a   Kostenuik, Paul ^b  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

^b AMGEN INC   (United States)

Author keywords

Femoral head deformity; Legg Calve Perthes disease; Osteonecrosis; Osteoprotegerin; RANKL

Indexed keywords

HUMAN OSTEOPROTEGERIN FRAGMENT CRYSTALLIZABLE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE MATRIX; BONE NECROSIS; BONE RADIOGRAPHY; CONTROLLED STUDY; DRUG ACTIVITY; EPIPHYSIS; FEMUR HEAD; FEMUR MALFORMATION; IMMUNOHISTOCHEMISTRY; INFARCTION; ISCHEMIA; MORPHOMETRICS; NONHUMAN; OSTEOARTHRITIS; OSTEOCLAST; OSTEOLYSIS; PERTHES DISEASE; SWINE; TRABECULAR BONE;

ANIMALS; BRAIN INFARCTION; DISEASE MODELS, ANIMAL; FEMUR HEAD; HUMANS; ISCHEMIA; LEGG-PERTHES DISEASE; OSTEOPROTEGERIN; RANK LIGAND; SWINE; TIME FACTORS;

EID: 33845206554     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.060905     Document Type: Article

References (50)

1. Aronson J 1986 Osteoarthritis of the young adult hip: Etiology and treatment. In: Anderson L (ed.) Instructional Course Lectures, vol. 35. American Academy of Orthopaedic Surgeons, Park Ridge, IL, USA, pp. 119-128.
2. Mc Andrew M, Weinstein SL 1984 A long-tern follow-up of Legg-Calve-Perthes disease. J Bone Joint Surg Am 66:860-869.
3. Catterall A, Pringle J, Byers PD, Fulford GE, Kemp HBS, Dolman CL, Bell HM, McKibbin B, Ralis Z, Jensen OM, Lauritzen J, Ponseti IV, Ogden J 1982 A review of the morphology of Perthes' disease. J Bone Joint Surg Br 64:269-275.
4. Jonsater S 1953 Coxa plana. A histo-pathologic and arthographic study. Acta Orthop Scand Suppl 12:25-54.
5. Jensen OM, Lauritzen J 1976 Legg-Calve-Perthes' disease - morphological studies in two cases examined at necropsy. J Bone Joint Surg Br 58:332-338.
6. McKibbin B, Ralis Z, Wales C 1974 Pathological changes in a case of Perthes' disease. J Bone Joint Surg Br 56:438-447.
7. Weinstein SL 1996 Legg-Calve-Perthes syndrome. In: Morrisy RT, Weinstein SL (eds.) Lovell and Winter's Pediatric Orthopaedics, 4th ed., vol. II. Lippincott-Raven, Philadelphia, PA, USA, pp. 951-991.
8. Kim HK, Su PH 2002 Development of flattening and apparent fragmentation following ischemic necrosis of the capital femoral epiphysis in a piglet model. J Bone Joint Surg Am 84:1329-1334.
9. Astrand J, Aspenberg P 2002 Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats. BMC Musculoskelet Disord 3:19-23.
10. Kim HK, Randall TS, Bian H, Jenkins J, Garces A, Bauss F 2005 Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J Bone Joint Surg Am 87:550-557.
11. Little DG, Peat RA, McEvoy A, Williams PR, Smith EJ, Baldock PA 2003 Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res 18:2016-2022.
12. Little DG, McDonald M, Sharpe IT, Peat R, Williams P, McEvoy T 2005 Zoledronic acid improves femoral head sphericity in a rat model of perthes disease. J Orthop Res 23:862-868.
13. Agarwala S, Jain D, Joshi VR, Sule A 2005 Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatol 44:352-359.
14. Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM 2005 The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 87:2155-2159.
15. Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423:337-342.
16. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D 2004 The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15:457-475.
17. Kostenuik PJ, Shalhoub V 2001 Osteoprotegerin: A physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7:613-635.
18. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
19. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
20. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
21. Kim HKW, Su P-H, Qiu Y-S 2001 Histopathologic changes in growth plate cartilage following ischemic necrosis of the capital femoral epiphysis. J Bone Joint Surg Am 83:688-697.
22. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR 2001 The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348-360.
23. Pringle D, Koob TJ, Kim HK 2004 Indentation properties of growing femoral head following ischemic necrosis. J Orthop Res 22:122-130.
24. Heyman CH, Herndon CH 1950 Legg-Perthes disease: A method for the measurement of the roentgenographic result. J Bone Joint Surg Am 32:767-778.
25. Weile U, Finsler S, Wehr U, Claus R 2001 Comparison of blood markers for the longitudinal monitoring of osteoclastic activity in the pig. J Vet Med A Physiol Pathol Clin Med 48:609-618.
26. Eriksen EF, Axelrod DW, Melsen F 1994 Bone Histomorphometry. Raven Press, New York, NY, USA.
27. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM 2004 A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059-1066.
28. Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM 2002 In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 17:192-199.
29. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS 2000 Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463-474.
30. Morony S, Warmington K, Adamu S, Asuncion F, Geng Z, Grisanti M, Tan HL, Capparelli C, Starnes C, Weimann B, Dunstan CR, Kostenuik PJ 2005 The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 146:3235-3243.
31. Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR 2001 Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 61:2572-2578.
32. Redlich K, Gortz B, Hayer S, Zwerina J, Doerr N, Kostenuik P, Bergmeister H, Kollias G, Steiner G, Smolen JS, Schett G 2004 Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol 164:543-555.
33. Mose K 1980 Methods of measuring in Legg-Calve-Perthes Disease with special regard to the prognosis. Clin Orthop 150:103-109.
34. Stulberg SD, Cooperman DR, Wallensten R 1981 The natural history of Legg-Calve-Perthes disease. J Bone Joint Surg Am 63:1095-1108.
35. Yrjonen T 1999 Long-term prognosis of Legg-Calve-Perthes disease: A meta-analysis. J Pediatr Orthop B 8:169-172.
36. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ 2001 Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimenlal bone metastasis. Cancer Res 61:4432-4436.
37. Ritchlin CT, Schwarz EM, O'Keefe RJ, Looney RJ 2004 RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. J Musculoskelet Neuronal Interact 4:276-284.
38. Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, Dunstan CR, Martin TJ, Gillespie MT 2002 Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 161:1419-1427.
39. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S 1999 Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255:491-494.
40. Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR 2001 OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142:4295-4304.
41. Valenta A, Roschger P, Fratzl-Zelman N, Kostenuik PJ, Dunstan CR, Fratzl P, Klaushofer K 2005 Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Bone 37:87-95.
42. Schett G, Middleton S, Bolon B, Stolina M, Brown H, Zhu L, Pretorius J, Zack DJ, Kostenuik P, Feige U 2005 Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum 52:1604-1611.
43. Fleisch H 1998 Bisphosphonates: Mechanisms of action. Endocr Rev 19:80-100.
44. Kim HK, Sanders M, Athavale S, Bian H, Bauss F 2006 Local bioavailability and distribution of systemically (parenterally) administered ibandronate in the infarcted femoral head. Bone 39:205-212.
45. Lin JH 1996 Bisphosphonates: A review of their pharmacokinetic properties. Bone 18:75-85.
46. Rodan GA 1998 Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 38:375-388.
47. Lepola VT, Hannuniemi R, Kippo K, Lauren L, Jalovaara P, Vaananen HK 1996 Long-term effects of clodronate on growing rat bone. Bone 18:191-196.
48. Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, Norimatsu H 2001 Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res 16:429-436.
49. Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, Toledano TR, Boskey AL 2001 A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int 69:94-101.
50. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ 2003 A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97:887-892.